stock performance explained
The sale of Cystistat provides a one-time boost to the books, but will reduce the company's revenue now and in the future.
The FDA fast-track announcement does nothing to alter the revenue situation at this time. Any difference it makes is years away from being realized.
The stock price has more to do with short-term stockholders who focus on the next quarter's results, and they have little reason to celebrate.
Approval of the e coli vaccine (if and when it arrives) should provide a real boost to the share price if and when it translates into increased revenue and income.
Best of luck to all.
QA